Belkin Vision device
America’s Alcon Pharmaceuticals is buying out Israeli healthtech company Belkin Vision, which has developed a laser treatment for glaucoma. The deal is for as much as $335 million, with $60 million to be paid now. Belkin is a fully homegrown Israeli firm, from start to finish, which was founded by and named for the scientist who developed its technology, Michael Belkin.
Founded in 2013 by Professor Michael Belkin, Belkin Vision boasts the firm has developed an efficient, non-contact, and automated glaucoma laser therapy accessible to all ophthalmologists. The Belkin Vision Eagle is currently available for sale in the EU and the UK. It is 510(k) cleared in the United States but is not yet available for sale. The Eagle device is indicated for use in selective laser trabeculoplasty (SLT). Nothing herein is intended to promote an off-label use of the Eagle device. The Eagle device is not intended to treat, cure, prevent or mitigate any specific disease.
Prof. Belkin received an M.A. degree in Science from Cambridge University, England, and an M.D. degree in Medicine from the Hebrew University of Jerusalem, Israel. He is the author of over 250 scientific publications and holds over 25 patents. Prof Belkin established and was the first full-time director of the Tel Aviv University Eye Research Institute.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Prof. Belkin has been involved in the establishment of many medical start-ups in ophthalmology and other fields. One of his noted contributions was inventing and developing the Ex-PRESS Glaucoma Filtration Device. The ExPRESS, after being sold to global eye care leader Alcon, is now routinely used in glaucoma surgery worldwide. He is now developing his latest invention, a one-second glaucoma laser treatment, for which he received a 2.5 million Euro grant from the European community.
Alcon is the largest eye care device company in the world, operating in the ophthalmic surgical and vision care markets, which are large, dynamic and growing. Their surgical and Vision Care products are used by more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors.
